Skip to main content
SpringerLink
Log in

Treatment with Statins in High-Risk Patients

Relevance of Time to Titration of Dose and Adverse Outcomes

  • Correspondence
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival study. Arch Intern Med 1996; 156: 2085–92.

    Article  PubMed  CAS  Google Scholar 

  2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events trial Investigators. N Eng J Med 1996; 335: 1001–9.

    Article  CAS  Google Scholar 

  3. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002; 106: 3143–421.

    Google Scholar 

  4. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003; 361: 2005–16.

    Article  PubMed  Google Scholar 

  5. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Eng J Med 2004; 350:1495–504.

    Article  CAS  Google Scholar 

  6. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published erratum appears in: Circulation 2004; 110: 763]. Circulation 2004; 110:227–39.

    Article  Google Scholar 

  7. Friend AS, Kamalesh M, Schellhase E, et al. Effect of time to titration to maximum dose of statins on cardiovascular outcomes. Am J Cardiovasc Drugs 2009; 9 (2): 103–7.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The author has consulted and spoken for various pharmaceutical companies including Pfizer, Inc., Merck & Co., Bayer HealthCare, CV Therapeutics, Bristol Myers Squibb, etc. The University of Oklahoma receives research grants from various pharmaceutical companies for studies in which the author is an investigator. The author receives no money for participation in those studies and has no conflicts of interest relevant to the contents of this letter.

Author information

Authors and Affiliations

  1. Department of Medicine, Cardiovascular Section, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA

    Udho Thadani

  2. Department of Veterans Affairs Medical Center, Medical Service, Cardiology, Oklahoma City, Oklahoma, USA

    Udho Thadani

Authors
  1. Udho Thadani
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thadani, U. Treatment with Statins in High-Risk Patients. Am J Cardiovasc Drugs 9, 211–212 (2009). https://doi.org/10.1007/BF03256576

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03256576

Keywords

Search

Navigation